Pelthos Therapeutics Inc. (PTHS) Income Statement
PTHS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPTHS revenue and net income
Where PTHS's revenue goes
2025Each bar shows an amount and its share of revenue. PTHS kept −257.9% of revenue as net income.
PTHS profit margins
PTHS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | +142.6% | — |
| Gross profit | — | — | +106.1% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PTHS quarterly EPS vs estimates
Pelthos Therapeutics beat the analyst EPS estimate in 2 of the last 7 quarters. Next report: November 12, 2026 (estimate $-2.83).
PTHS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $16.8M | $0 | $0 | $0 | $0 | $199,934 |
| Cost of revenue | $9.4M | $0 | — | — | — | $0 |
| Gross profit | $7.4M | $0 | — | — | — | $199,934 |
| Research & development | $1.2M | $1.2M | $2.6M | $391,730 | $209,047 | $138,585 |
| Sales, general & admin | $37.1M | $6.4M | $4.3M | $1.9M | $629,949 | — |
| Total operating expenses | $39.9M | $7.6M | $6.9M | $2.3M | $838,996 | $1.6M |
| Operating income | −$32.4M | −$7.6M | −$6.9M | −$2.3M | −$838,996 | −$1.4M |
| Interest income | $5,000 | $402,000 | — | — | — | — |
| Interest expense | $3.0M | $786,393 | $518,509 | $140,430 | $253 | $1,676 |
| Income before taxes | −$50.7M | −$8.0M | −$7.4M | −$2.5M | −$595,387 | −$660,584 |
| Income taxes | −$7.4M | — | — | — | — | — |
| Net income | −$43.3M | −$8.0M | −$7.4M | −$2.5M | −$595,387 | −$660,584 |
| EBITDA | −$45.4M | −$7.2M | −$6.9M | −$2.3M | −$595,134 | −$658,908 |
| EPS (diluted) | −$16.58 | −$11.82 | −$12.56 | −$2.46 | — | — |
| Gross margin | 44.2% | — | — | — | — | 100.0% |
| Operating margin | −193.1% | — | — | — | — | −677.2% |
| Net margin | −257.9% | — | — | — | — | −330.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.6M | $10.9M | $9.4M | $7.4M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $4.9M | $5.3M | $4.4M | $5.0M | $0 | $0 | — | $0 | — | — | — |
| Gross profit | $10.7M | $5.6M | $5.0M | $2.4M | $0 | $0 | — | $0 | — | — | — |
| Research & development | $600,000 | $186,000 | $374,000 | $145,000 | $514,814 | $194,298 | $285,236 | $414,639 | $12,955 | $466,606 | $2.3M |
| Sales, general & admin | $18.5M | $17.5M | $15.8M | $17.0M | $2.7M | $1.6M | $1.5M | $1.6M | $1.8M | $1.5M | — |
| Total operating expenses | $28.0M | $18.7M | $17.0M | $17.8M | $3.2M | $1.8M | $1.8M | $2.0M | $1.8M | $1.9M | $3.9M |
| Operating income | −$17.3M | −$13.1M | −$12.0M | −$15.4M | −$3.2M | −$1.8M | −$1.8M | −$2.0M | −$1.8M | −$1.9M | −$3.9M |
| Interest income | — | — | $0 | $5,000 | $0 | — | — | $393,000 | $3,527 | — | — |
| Interest expense | $2.4M | $2.4M | $1.3M | $1.3M | $218,516 | $133,634 | $107,966 | $39,019 | $11,060 | $628,348 | $160,338 |
| Income before taxes | −$23.4M | −$10.2M | −$28.6M | −$16.7M | −$3.4M | −$2.0M | −$1.9M | −$1.7M | −$1.8M | −$2.6M | −$4.0M |
| Income taxes | — | — | −$6.9M | −$465,000 | — | — | — | — | — | — | — |
| Net income | −$23.4M | −$10.2M | −$21.7M | −$16.2M | −$3.4M | −$2.0M | −$1.9M | −$1.7M | −$1.8M | −$2.6M | −$4.0M |
| EBITDA | −$15.9M | −$6.4M | −$26.1M | −$14.2M | −$3.2M | −$1.8M | −$1.8M | −$1.7M | −$1.8M | −$1.9M | −$3.9M |
| EPS (diluted) | −$6.62 | −$4.66 | −$2.69 | −$5.30 | −$5.38 | −$3.21 | −$0.32 | −$2.90 | −$3.10 | −$5.50 | — |
| Gross margin | 68.4% | 51.3% | 53.2% | 32.8% | — | — | — | — | — | — | — |
| Operating margin | −111.0% | −120.0% | −127.8% | −207.4% | — | — | — | — | — | — | — |
| Net margin | −150.1% | −93.9% | −230.7% | −219.3% | — | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PTHS's financial statements (latest annual report filed March 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PTHS financial results
In fiscal year 2025 (ended December 31, 2025), Pelthos Therapeutics reported revenue of $16.8 million. It had a net loss of $43.3 million, a net profit margin of −257.9%. Diluted earnings per share came to −$16.58. Over five years revenue grew at an average rate of 142.6% a year.
See the PTHS stock overview for the latest quote and news, or the PTHS chart for price history and technical indicators.
PTHS income statement FAQ
What is Pelthos Therapeutics's annual revenue?
Pelthos Therapeutics reported total revenue of $16.8 million for fiscal year 2025, which ended on December 31, 2025.
Is Pelthos Therapeutics profitable?
No. Pelthos Therapeutics reported a net loss of $43.3 million in fiscal 2025, a net profit margin of −257.9%; its operating margin was −193.1%.
What is Pelthos Therapeutics's gross margin?
Pelthos Therapeutics's gross margin was 44.2% in fiscal 2025: for every $100 of revenue, Pelthos Therapeutics kept $44 after the direct cost of its products and services.
How much does Pelthos Therapeutics spend on research and development?
Pelthos Therapeutics spent $1.2 million on research and development in fiscal 2025, 7.3% of revenue.
How fast is Pelthos Therapeutics growing?
Revenue grew 142.6% a year on average over the last five fiscal years, from $0.2 million to $16.8 million.
What are Pelthos Therapeutics's earnings per share?
Pelthos Therapeutics earned $-16.58 per diluted share in fiscal 2025, compared with $-11.82 a year earlier.
When will Pelthos Therapeutics report its next earnings?
Pelthos Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens.
When does Pelthos Therapeutics's fiscal year end?
Pelthos Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 19, 2026.